低分子肝素联合参芎注射液治疗肿瘤静脉血栓栓塞分析

Low molecular weight heparin combined with shenxiong injection treatment for tumor patients with venous thromboembolism

目的观察低分子肝素联合参芎注射液治疗肿瘤静脉血栓栓塞的临床疗效。方法选取2010-2011年我院收治的恶性肿瘤患者共24例,随机分为治疗组和对照组,每组12例。对照组仅予低分子肝素(速碧林)治疗,85 IU/kg皮下注射,治疗组在对照组的基础上给予参芎注射液200 mL静滴。两组患者的疗程均为15d。结果治疗组总有效率(100%)明显高于对照组(83.3%),两组比较差异有统计学意义(P<0.05)。两组患者在用药期间均未发生出血倾向及过敏反应。结论低分子肝素联合参芎注射液治疗肿瘤静脉血栓栓塞,效果显著,未见明显的不良反应。

Objective To observe the clinical efficacy of low molecular weight heparin combined with shenxlong injection treatment for tumor patients with venous thromboembolism. Methods 24 cases with malignant tumors in our hospital were randomly divided into treatment group and control group, 12 cases each group. The patients of control group were only given low molecular weight heparin（ nadroparin）, 85 IU/kg. On the basis therapy of control group, the patients of treatment group were given shenxiong injection, 200 mL intravenous. The therapeutic time of both groups lasted 15 d. Results The total efficacy of treatment group was significantly higher than that of control group（ 100% vs. 83. 3 % ）, there was significant difference between the two groups （ P 〈 0. 05 ）. The patients of the two groups did not have bleeding tendency and allergic reactions during the treatment. Conclusion The effect of the low molecular weight heparin combined with shenxiong injection treatment for tumor patients with venous thromboembolism is better and has less adverse reactions.